A comparative clinico-experimental evaluation of Rasayana Drugs administered orally & by Basti in the management of Madhumeha w. s. r. to Type-II Diabetes Mellitus

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2013/05/003705

Enrollment

100

Registered

2013-05-30

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Type 2 Diabetes Mellitus

Interventions

Intervention1: Group B: Rasayana Kashaya in a dose of 100ml daily in two divided doses before meal for 21 days Intervention2: Basti: Madanaphala Taila Anuvasana 160 ml followed by three Rasayana Bast

in a schedule of 21 days Intervention3: Rasayana Kashaya: Rasayana Kashaya in a dose of 100ml daily in two divided doses before meal for 21 days Control Intervention1: Placebo: Placebo capsule contain

Eligibility

Inclusion criteria

Inclusion criteria: Patient of NIDDM with blood sugar level, FBS- 126 to 220 mg/dl or PPBS- 180 to 300 mg/dl.

Exclusion criteria

Exclusion criteria: Patients having age less than 20 years & above 60 years. Patients of Type-I Diabetes or the patients of Type-II Diabetes taking Insulin. Patients having complications of Diabetes like Nephropathy, Retinopathy, Diabetic Foot, Carbuncles etc. Patients having Diabetes in association with other endocrinopathies like Phaeochromocytoma, Acromegaly, Cushingâ??s syndrome, hyperthyroidism etc. Patients having drug or chemical induced Type II Diabetes, like glucocorticoids induced or thyroid hormone induced etc. Patients with genetic syndromes associated with Type II Diabetes like Downâ??s Syndrome, Klinefelterâ??s Syndrome, Turnerâ??s Syndrome etc. Patients complicated with any Cardiovascular diseases, Renal diseases, Carcinoma or any other disease effecting multiple body systems and pregnant women etc. Patients contraindicated for Bastikarma as per classics

Design outcomes

Primary

Measure	Time frame
blood sugar reduction and reduction in sign and symptoms of diabetes mellitus type 2Timepoint: 21 days	—

Secondary

Measure	Time frame
reduction in sign and symptoms of MadhumehaTimepoint: 21 days	—

Countries

India

Contacts

Public ContactSwapnil Shivaji Auti

Institute for Post Graduate Teaching & Research in Ayurveda, Gujarat Ayurved University

anup_thakar@yahoo.com9427776660

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026